|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pourhoseingholi MA, Vahedi M and
Baghestani AR: Burden of gastrointestinal cancer in Asia; an
overview. Gastroenterol Hepatol Bed Bench. 8:19–27. 2015.PubMed/NCBI
|
|
3
|
Zeng H, Zheng R, Guo Y, Zhang S, Zou X,
Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in
China, 2003–2005: A population-based study. Int J Cancer.
136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lagergren J and Lagergren P: Recent
developments in esophageal adenocarcinoma. CA Cancer J Clin.
63:232–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson DG and Walker CL: Cyclins and cell
cycle checkpoints. Annu Rev Pharmacol Toxicol. 39:295–312. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wolgemuth DJ and Roberts SS: Regulating
mitosis and meiosis in the male germ line: Critical functions for
cyclins. Philos Trans R Soc Lond B Biol Sci. 365:1653–1662. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kronja I and Orr-Weaver TL: Translational
regulation of the cell cycle: When, where, how and why? Philos
Trans R Soc Lond B Biol Sci. 366:3638–3652. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, Fei M, Cheng C, Zhang D, Lu J, He
S, Zhao Y, Wang Y and Shen A: Jun activation domain-binding protein
1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas. Cancer
Biol Ther. 7:460–467. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song Y, Zhao C, Dong L, Fu M, Xue L, Huang
Z, Tong T, Zhou Z, Chen A, Yang Z, et al: Overexpression of cyclin
B1 in human esophageal squamous cell carcinoma cells induces tumor
cell invasive growth and metastasis. Carcinogenesis. 29:307–315.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takeno S, Noguchi T, Kikuchi R, Uchida Y,
Yokoyama S and Müller W: Prognostic value of cyclin B1 in patients
with esophageal squamous cell carcinoma. Cancer. 94:2874–2881.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nozoe T, Korenaga D, Kabashima A, Ohga T,
Saeki H and Sugimachi K: Significance of cyclin B1 expression as an
independent prognostic indicator of patients with squamous cell
carcinoma of the esophagus. Clin Cancer Res. 8:817–822.
2002.PubMed/NCBI
|
|
12
|
Chetty R and Simelane S: p53 and cyclin A
protein expression in squamous carcinoma of the oesophagus. Pathol
Oncol Res. 5:193–196. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bernis C, Vigneron S, Burgess A, Labbé JC,
Fesquet D, Castro A and Lorca T: Pin1 stabilizes Emi1 during G2
phase by preventing its association with SCF(betatrcp). EMBO Rep.
8:91–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller JJ, Summers MK, Hansen DV, Nachury
MV, Lehman NL, Loktev A and Jackson PK: Emi1 stably binds and
inhibits the anaphase-promoting complex/cyclosome as a
pseudosubstrate inhibitor. Genes Dev. 20:2410–2420. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moshe Y, Bar-On O, Ganoth D and Hershko A:
Regulation of the action of early mitotic inhibitor 1 on the
anaphase-promoting complex/cyclosome by cyclin-dependent kinases. J
Biol Chem. 286:16647–16657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reimann JD, Gardner BE, Margottin-Goguet F
and Jackson PK: Emi1 regulates the anaphase-promoting complex by a
different mechanism than Mad2 proteins. Genes Dev. 15:3278–3285.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reimann JD, Freed E, Hsu JY, Kramer ER,
Peters JM and Jackson PK: Emi1 is a mitotic regulator that
interacts with Cdc20 and inhibits the anaphase promoting complex.
Cell. 105:645–655. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu JY, Reimann JD, Sørensen CS, Lukas J
and Jackson PK: E2F-dependent accumulation of hEmi1 regulates S
phase entry by inhibiting APC (Cdh1). Nat Cell Biol. 4:358–366.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Margottin-Goguet F, Hsu JY, Loktev A,
Hsieh HM, Reimann JD and Jackson PK: Prophase destruction of Emi1
by the SCF (betaTrCP/Slimb) ubiquitin ligase activates the anaphase
promoting complex to allow progression beyond prometaphase. Dev
Cell. 4:813–826. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu
C, Shen A, Wang Y, Li C, Yuan Q, et al: Early mitotic inhibitor-1,
an anaphase-promoting complex/cyclosome inhibitor, can control
tumor cell proliferation in hepatocellular carcinoma: Correlation
with Skp2 stability and degradation of p27(Kip1). Hum Pathol.
44:365–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masunaga R, Kohno H, Dhar DK, Ohno S,
Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H and
Nagasue N: Cyclooxygenase-2 expression correlates with tumor
neovascularization and prognosis in human colorectal carcinoma
patients. Clin Cancer Res. 6:4064–4068. 2000.PubMed/NCBI
|
|
22
|
Roth JA and Cristiano RJ: Gene therapy for
cancer: What have we done and where are we going? J Natl Cancer
Inst. 89:21–39. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roncalli M, Bosari S, Marchetti A,
Buttitta F, Bossi P, Graziani D, Peracchia A, Bonavina L, Viale G
and Coggi G: Cell cycle-related gene abnormalities and product
expression in esophageal carcinoma. Lab Invest. 78:1049–1057.
1998.PubMed/NCBI
|
|
25
|
Gütgemann I, Lehman NL, Jackson PK and
Longacre TA: Emi1 protein accumulation implicates misregulation of
the anaphase promoting complex/cyclosome pathway in ovarian clear
cell carcinoma. Mod Pathol. 21:445–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu X, Wang H, Ma J, Xu J, Sheng C, Yang
S, Sun L and Ni Q: The expression and prognosis of Emi1 and Skp2 in
breast carcinoma: Associated with PI3K/Akt pathway and cell
proliferation. Med Oncol. 30:7352013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sheri A and Dowsett M: Developments in
Ki67 and other biomarkers for treatment decision making in breast
cancer. Ann Oncol. 23(Suppl 10): x219–x227. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He WL, Li YH, Yang DJ, Song W, Chen XL,
Liu FK, Wang Z, Li W, Chen W, Chen CY, et al: Combined evaluation
of centromere protein H and Ki-67 as prognostic biomarker for
patients with gastric carcinoma. Eur J Surg Oncol. 39:141–149.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harbour JW and Dean DC: The Rb/E2F
pathway: Expanding roles and emerging paradigms. Genes Dev.
14:2393–2409. 2000. View Article : Google Scholar : PubMed/NCBI
|
